Wire · opportunities
Teleflex wins Breakthrough Device designation for Freesolve resorbable scaffold
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 October 2026 · Fusion42 review
Teleflex's Freesolve resorbable magnesium scaffold has received FDA Breakthrough Device designation for percutaneous coronary intervention, accelerating its development and regulatory review in the US market. The device offers a novel treatment option by providing temporary vessel support with full magnesium absorption after one year, potentially reducing the need for permanent implants in coronary therapy.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You must reassess your US market access plans as Freesolve's breakthrough status speeds Teleflex's entry and raises the bar for coronary intervention devices with resorbable technology. This designation opens a quicker path to adoption that could shift physician preference away from permanent implants.
◆ Coverage
1 source · 22 Oct 2026
◆ Related on Wire
◆ Topics